These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37879536)

  • 21. A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer.
    Galffy G; Lugowska I; Poddubskaya EV; Cho BC; Ahn MJ; Han JY; Su WC; Hauke RJ; Dyar SH; Lee DH; Serwatowski P; Estelles DL; Holden VR; Kim YJ; Vladimirov V; Horvath Z; Ghose A; Goldman A; di Pietro A; Wang J; Murphy DA; Alhadab A; Laskov M
    ESMO Open; 2023 Jun; 8(3):101173. PubMed ID: 37141847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Nonsquamous Versus Squamous NSCLC.
    Doroshow DB; Wei W; Gupta S; Zugazagoitia J; Robbins C; Adamson B; Rimm DL
    J Thorac Oncol; 2021 Dec; 16(12):2139-2143. PubMed ID: 34455068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
    Mok TSK; Wu YL; Kudaba I; Kowalski DM; Cho BC; Turna HZ; Castro G; Srimuninnimit V; Laktionov KK; Bondarenko I; Kubota K; Lubiniecki GM; Zhang J; Kush D; Lopes G;
    Lancet; 2019 May; 393(10183):1819-1830. PubMed ID: 30955977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
    Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
    Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101).
    Lakhani N; Cosman R; Banerji U; Rasco D; Tomaszewska-Kiecana M; Garralda E; Kornacki D; Li J; Tian C; Bourayou N; Powderly J
    ESMO Open; 2024 Apr; 9(4):102254. PubMed ID: 38387109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial.
    Lu S; Wang J; Yu Y; Yu X; Hu Y; Ai X; Ma Z; Li X; Zhuang W; Liu Y; Li W; Cui J; Wang D; Liao W; Zhou J; Wang Z; Sun Y; Qiu X; Gao J; Bao Y; Liang L; Wang M
    J Thorac Oncol; 2021 Sep; 16(9):1512-1522. PubMed ID: 34033975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors.
    Sato J; Shimizu T; Koyama T; Iwasa S; Shimomura A; Kondo S; Kitano S; Yonemori K; Fujiwara Y; Tamura K; Suzuki T; Takase T; Nagai R; Yamaguchi K; Semba T; Zhao ZM; Ren M; Yamamoto N
    Clin Cancer Res; 2022 May; 28(9):1783-1791. PubMed ID: 35180771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer.
    Cho BC; Yoh K; Perets R; Nagrial A; Spigel DR; Gutierrez M; Kim DW; Kotasek D; Rasco D; Niu J; Satouchi M; Ahn MJ; Lee DH; Maurice-Dror C; Siddiqi S; Ren Y; Altura RA; Bar J
    Lung Cancer; 2021 Sep; 159():162-170. PubMed ID: 34371366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial.
    Provencio M; Ortega AL; Coves-Sarto J; Calvo V; Marsé-Fabregat R; Dómine M; Guirado M; Carcereny E; Fernández N; Álvarez R; Blanco R; León-Mateos L; Sánchez-Torres JM; Sullivan IG; Cobo M; Sánchez-Hernández A; Massuti B; Sierra-Rodero B; Mártinez-Toledo C; Serna-Blasco R; Romero A; Cruz-Bermúdez A
    JAMA Oncol; 2023 Mar; 9(3):344-353. PubMed ID: 36520426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer: a prospective, single-arm, phase II study in China.
    Han X; Guo J; Tang X; Zhu H; Zhu D; Zhang X; Meng X; Hua Y; Wang Z; Zhang Y; Huang W; Wang L; Yuan S; Zhang P; Gong H; Sun Y; Zhang Y; Liu Z; Wang Z
    J Cancer Res Clin Oncol; 2023 Apr; 149(4):1443-1451. PubMed ID: 35482078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
    Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
    JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
    Cho BC; Abreu DR; Hussein M; Cobo M; Patel AJ; Secen N; Lee KH; Massuti B; Hiret S; Yang JCH; Barlesi F; Lee DH; Ares LP; Hsieh RW; Patil NS; Twomey P; Yang X; Meng R; Johnson ML
    Lancet Oncol; 2022 Jun; 23(6):781-792. PubMed ID: 35576957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis.
    Alifu M; Tao M; Chen X; Chen J; Tang K; Tang Y
    Front Oncol; 2023; 13():1146905. PubMed ID: 37397392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G
    Sheng X; Yan X; Chi Z; Si L; Cui C; Tang B; Li S; Mao L; Lian B; Wang X; Bai X; Zhou L; Kong Y; Dai J; Wang K; Tang X; Zhou H; Wu H; Feng H; Yao S; Flaherty KT; Guo J
    J Clin Oncol; 2019 Nov; 37(32):2987-2999. PubMed ID: 31403867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study.
    Verschraegen CF; Jerusalem G; McClay EF; Iannotti N; Redfern CH; Bennouna J; Chen FL; Kelly K; Mehnert J; Morris JC; Taylor M; Spigel D; Wang D; Grote HJ; Zhou D; Munshi N; Bajars M; Gulley JL
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32907924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2).
    Spigel D; Jotte R; Nemunaitis J; Shum M; Schneider J; Goldschmidt J; Eisenstein J; Berz D; Seneviratne L; Socoteanu M; Bhanderi V; Konduri K; Xia M; Wang H; Hozak RR; Gueorguieva I; Ferry D; Gandhi L; Chao BH; Rybkin I
    J Thorac Oncol; 2021 Feb; 16(2):327-333. PubMed ID: 33166722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
    Wang J; Lu S; Yu X; Hu Y; Sun Y; Wang Z; Zhao J; Yu Y; Hu C; Yang K; Feng G; Ying K; Zhuang W; Zhou J; Wu J; Leaw SJ; Zhang J; Lin X; Liang L; Yang N
    JAMA Oncol; 2021 May; 7(5):709-717. PubMed ID: 33792623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC.
    Antonia SJ; Balmanoukian A; Brahmer J; Ou SI; Hellmann MD; Kim SW; Ahn MJ; Kim DW; Gutierrez M; Liu SV; Schöffski P; Jäger D; Jamal R; Jerusalem G; Lutzky J; Nemunaitis J; Calabrò L; Weiss J; Gadgeel S; Bhosle J; Ascierto PA; Rebelatto MC; Narwal R; Liang M; Xiao F; Antal J; Abdullah S; Angra N; Gupta AK; Khleif SN; Segal NH
    J Thorac Oncol; 2019 Oct; 14(10):1794-1806. PubMed ID: 31228626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
    Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
    Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.
    Yu EY; Kolinsky MP; Berry WR; Retz M; Mourey L; Piulats JM; Appleman LJ; Romano E; Gravis G; Gurney H; Bögemann M; Emmenegger U; Joshua AM; Linch M; Sridhar S; Conter HJ; Laguerre B; Massard C; Li XT; Schloss C; Poehlein CH; de Bono JS
    Eur Urol; 2022 Jul; 82(1):22-30. PubMed ID: 35397952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.